| Title | Pharmacotherapy of multiple sclerosis: the PROOF trial. | | Author(s) | Boster A, Racke MK | | Institution | The Ohio State University Medical Center, Department of Neurology, 395 West 12th Avenue, Room 792, Columbus, Ohio 43210, USA +1 614 293 4036 ; +1 614 293 9029 ; Michael.Racke@osumc.edu. | | Source | Expert Opin Pharmacother 2009 Jun; 10(8):1235-7. | | Abstract | Background: Currently approved disease-modifying therapies for relapsing-remitting multiple sclerosis (RRMS) include two different interferon beta-1a (IFNB-1a) preparations: subcutaneous IFNB-1a (Rebif((c))) 44 mug three times weekly and intramuscular IFNB-1a (Avonex((c))) 30 mug once weekly.
Objective: This evaluation is of the Prospective and Retrospective Long-Term Observational Study of Avonex and Rebif (PROOF), which intended to compare relative efficacy and tolerability of the two INFB-1a products.
Methods: PROOF was analyzed in light of previous head-to-head studies comparing high- and low-frequency IFNB therapies. Results/conclusions: Several limitations, including a retrospective-prospective design, retrospective assessment of variables without predefined criteria, limited prospective evaluation, and inadequate sample size, necessitate careful interpretation of their
Results. Ultimately, the question of long-term efficacy of high- versus low-frequency INFB therapies remains unanswered. | | Language | eng | | Pub Type(s) | Journal Article
| | PubMed ID | 19463066 |
|
